+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Transplantation Market- Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

  • PDF Icon


  • 140 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5617077
UP TO OFF until Dec 31st 2023
The Transplantation Market is expected to register a CAGR of 9.9% during the forecast period, 2022-2027.

A major factor driving market growth is the rising demand for novel tissue transplantation products and organ transplantation to treat organ failure. According to the study published in Current Transplantation Reports, titled 'Diagnostic Testing of COVID-19 in Solid Organ Transplantation: Current Clinical Application and Future Strategies' in October 2020, multiple elements of solid organ transplantation have been impacted by the COVID-19 pandemic, including donor and recipient appropriateness, as well as infection and transmission prevention following transplantation. Moreover, according to the study titled "Epidemiology of Organ Failure Before and During COVID-19 Pandemic Surge Conditions," published in the American Journal of Critical Care in May 2022, during the pandemic, renal failure was the most common type of organ failure at admission and respiratory failure was the most common type of hospital-onset organ failure. The SARS-CoV-2-positive group showed a 231% increase in respiratory failure compared with the pre-pandemic group. Thus, with increasing organ failure, the demand for transplantation increases over the forecast period.

Moreover, the global demand for tissue and organ transplantation, particularly kidney, heart, liver, and lung transplantation, is extremely high. Organ failure is caused by a variety of factors, including poor dietary habits, excessive alcohol consumption, a lack of exercise, and drug abuse. As a result, transplantation product demand is expected to increase in the near future. The rising donation of organs is one of the biggest contributors to the growth of the market studied. According to the data published by the Association of Organ Procurement Organizations (AOPO) in January 2021, more than 12,500 people donated one or more organs in 2020, up 6% from the previous year. The number of organs donated from dead donors increased to over 36,500 in 2020, an increase of almost 2% year over year. For the seventh year in a running, these retrieved organs saved more than 33,000 lives, exceeding the previous year's totals. There were also notable increases in Donation after Circulatory Death (DCD) contributions, which totaled more than 3,000 donors, up 18% year over year.

Furthermore, rising in the prevalence of chronic diseases such as cancer and heart and kidney diseases is propelling the growth of the market. For Instance, in March 2020, as per data released on World Kidney Day, a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF), kidney disease affected around 850 million people globally. In addition, as per the Globocan 2020 report published by Global Cancer Observatory, which estimated the incidence and mortality of 36 cancer in 185 countries globally, there were an estimated 19,292,789 new cases of cancer diagnosed in 2020, and about 9,958,133 people died due to cancer.

Additionally, product launches by the key market players, as well as various strategies adopted by the market players such as mergers and acquisitions, are anticipated to boost the market over the forecast period. For Instance, in June 2021, transplant diagnostics company CareDx acquired New York-based Transplant Hero, the developer of a smartphone app that's aimed at supporting the needs of transplant patients. As a result of such initiatives by key market players, the transplantation product becomes more accessible, boosting the market growth.

Thus, all aforementioned factors are anticipated to boost the market over the forecast period. However, the shortage of organ donors and ethical and cultural issues restraint the market over the forecast period,

Key Market Trends

Tissue Product Segment is Expected to Dominate the Market Over the Forecast Period

Tissue donation is when tissues in the body (e.g., skin, corneas, bone) are removed from one person and transplanted into another person. The expansion of the segment is related to the increasing number of transplantation procedures such as cochlear, heart valves, bone marrow, and orthopedic soft tissues.

According to the Association of Organ Procurement Organization report in March 2022, Approximately 30,000 tissue donors contribute over 1.75 million life-saving and life-improving tissue transplants each year. Thus, increasing tissue transplantation is expected to boost the market over the forecast period.

Advancement in transplantation technology and the launch of new products by manufacturers is expected to propel the number of transplant procedures, including kidney, liver, heart, lungs, and tissues. For instance, in July 2021, Bioventus Inc. launched OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of patient procedures, including lumbar spine fusion, cervical spine fusion, and foot & ankle fusion.

Furthermore, partnerships, mergers, and acquisitions are supporting market expansion. For instance, in May 2022, Orthofix Medical renewed and expanded its partnership agreement with MTF Biologics. The collaboration extends Orthofix’s exclusive marketing rights to the Trinity allograft line through 2032 and includes an expansion agreement to develop a demineralized bone matrix (DBM) that Orthofix will market under the Legacy brand name.

Thus, all aforementioned factors are anticipated to boost the segment growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to hold a major share in the transplant diagnostics market and is expected to continue at the same pace over the forecast period.

Countries such as the United States and Canada have well-funded organizations, infrastructure, and government involvement in generating cash and creating awareness to encourage organ transplantation for patients. For instance, according to the National Institute of Health in June 2021, the fundings for the research in transplantation were USD 650 million, USD 733 million, and USD 721 million in 2018, 2019, and 2020 respectively. The rise in funding for transplantation research will therefore lead to increased utilization of transplants driving the growth of the market in this region.

Furthermore, according to the Health Resources and Services Administration, in February 2022, there will be over 106,000 people on the national transplant waiting list for solid organ transplantation in the United States. The percentage of people waiting for solid organ transplant includes Kidney (83%), liver (11%), Pancreas (1%), Heart (3%, Lung (%), and Others (2%). The rise in demand for solid organs will lead to increased testing for this segment, thereby expected to drive the growth of this segment over the forecast period. In addition, according to the Organ Donation Statistics published in February 2022, more than 40,000 organ transplantations have taken place in the United States in 2021. The rise in transplantations will therefore drive the growth of this market over the forecast period.

The rising prevalence of chronic diseases is anticipated to boost the market over the forecast period. According to the estimates of the American Cancer Society, in 2022, there were around 79,000 new cases of kidney cancer in the United States and approximately 13,920 deaths from this disease. As per the same source, kidney cancer is among the ten most common cancers in both men and women. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%). The lifetime risk for women is about 1 in 80 (1.03%).

Increasing product launches by the key market players are anticipated to boost the market over the forecast period. For instance, in July 2021, Orathofix Medical Inc. launched and first patient implants with the fiberFUSE Strip, an advanced demineralized fiber bone-graft solution containing cancellous bone.

With a large section of the population across the world approaching these two nations for better healthcare facilities, the region is expected to be very lucrative for growth and expected to hold a significant share in the market studied over the forecast period.

Competitive Landscape

The market is highly fragmented, with the presence of many large, small, and medium-scale vendors. Mergers and acquisitions support vendors in expanding their existing product portfolio and geographical reach. The players are involved in launching new products, mergers & acquisitions, and regional expansion to gain maximum revenue share in the industry. Some of the major players in the industry are Abbvie, Inc., Arthrex, Inc., Zimmer Biomet, Medtronic, Novartis AG, and Strykers.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Chronic Diseases
4.2.2 Increasing Burden of Organ Failure
4.2.3 Technological Advancement in Transplantation Method
4.3 Market Restraints
4.3.1 Shortage of Organ Donors
4.3.2 Ethical and Cultural Issues
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product
5.1.1 Tissue Products
5.1.2 Immunosuppressive Drugs
5.1.3 Preservation Solution
5.2 By Application
5.2.1 Organ Transplantation
5.2.2 Tissue Transplantation
5.3 By End Use
5.3.1 Hospitals
5.3.2 Transplant Centers
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Abbvie, Inc
6.1.2 Arthrex, Inc.
6.1.3 Zimmer Biomet
6.1.4 Medtronic
6.1.5 Novartis AG
6.1.6 Strykers
6.1.7 21st Century Medicine
6.1.8 BiolifeSolutions, Inc
6.1.9 Teva Pharmaceuticals
6.1.10 Orthofix Medical
6.1.11 Veloxis Pharmaceutical
6.1.12 Amnio Technology

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbvie, Inc
  • Arthrex, Inc.
  • Zimmer Biomet
  • Medtronic
  • Novartis AG
  • Strykers
  • 21st Century Medicine
  • BiolifeSolutions, Inc
  • Teva Pharmaceuticals
  • Orthofix Medical
  • Veloxis Pharmaceutical
  • Amnio Technology